These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 7392729)

  • 1. [Plasma concentration of oral anticoagulants--a clinically useful analysis].
    Ivermark CK; Orme M
    Lakartidningen; 1980 May; 77(20):1943-4. PubMed ID: 7392729
    [No Abstract]   [Full Text] [Related]  

  • 2. [The international normalization ratio in the monitoring of oral anticoagulant therapy].
    Sansores-García L; Majluf-Cruz AS; Vargas-Vorácková F; Labardini-Méndez J
    Rev Invest Clin; 1993; 45(5):463-7. PubMed ID: 8134728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Outpatient oral anticoagulant therapy].
    Stellfeld M; Hansen AC
    Ugeskr Laeger; 1987 Apr; 149(16):1055-8. PubMed ID: 3576822
    [No Abstract]   [Full Text] [Related]  

  • 4. Levels of prothrombin fragment F1+2 in patients with hyperhomocysteinemia and a history of venous thromboembolism.
    Kyrle PA; Stümpflen A; Hirschl M; Bialonczyk C; Herkner K; Speiser W; Weltermann A; Kaider A; Pabinger I; Lechner K; Eichinger S
    Thromb Haemost; 1997 Nov; 78(5):1327-31. PubMed ID: 9408013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurement of prothrombin time in patients on oral anticoagulant therapy: effect of two different evacuated tubes.
    D'Angelo G; Villa C
    Haematologica; 1999 Jul; 84(7):656-7. PubMed ID: 10406912
    [No Abstract]   [Full Text] [Related]  

  • 6. Relationship between international normalized ratio values, vitamin K-dependent clotting factor levels and in vivo prothrombin activation during the early and steady phases of oral anticoagulant treatment.
    D'Angelo A; Della Valle P; Crippa L; Fattorini A; Pattarini E; Viganò D'Angelo S
    Haematologica; 2002 Oct; 87(10):1074-80. PubMed ID: 12368163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Home use of an ambulatory monitor for the determination of prothrombin time (coaguchek) in patients treated with oral anticoagulants. Multicenter prospective study].
    Cosmi B; Palareti G; Moia M; Pengo V; Testa S
    Minerva Cardioangiol; 1999 Dec; 47(12):598-9. PubMed ID: 10670221
    [No Abstract]   [Full Text] [Related]  

  • 8. [Prothrombin fragment 1+2 (F1+2), thrombin-antithrombin III complex(TAT) and thrombophilia parameters in orally anticoagulated patients with inferior vena cava filters].
    Halbmayer WM; Haushofer A; Toth E
    Wien Med Wochenschr; 1993; 143(5):95-8. PubMed ID: 8511904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cataract surgery under topical anesthesia with oral anticoagulants].
    Wirbelauer C; Weller A; Häberle H; Pham DT
    Klin Monbl Augenheilkd; 2004 Sep; 221(9):749-52. PubMed ID: 15459841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Monitoring treatment with oral anticoagulants in non-hospitalized patients].
    Gianotti A; Bottino G; Moscatelli P
    G Clin Med; 1987; 68(6-7):357-8. PubMed ID: 3653579
    [No Abstract]   [Full Text] [Related]  

  • 11. Gender differences in pharmacokinetics of oral warfarin in rats.
    Zhu X; Shin WG
    Biopharm Drug Dispos; 2005 May; 26(4):147-50. PubMed ID: 15776499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An oral vitamin K protocol to reverse over-anticoagulation in patients presenting with an International Normalised Ratio above 10.0.
    Denas G; Cucchini U; Iliceto S; Pengo V
    Thromb Haemost; 2009 Feb; 101(2):410-1. PubMed ID: 19190831
    [No Abstract]   [Full Text] [Related]  

  • 13. Changes of prothrombin fragment 1+2 (F 1+2) as a function of increasing intensity of oral anticoagulation--considerations on the suitability of F 1+2 to monitor oral anticoagulant treatment.
    Tripodi A; Cattaneo M; Molteni A; Cesana BM; Mannucci PM
    Thromb Haemost; 1998 Mar; 79(3):571-3. PubMed ID: 9531043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring oral anticoagulant treatment from plasma stored for up to 48 hours and frozen plasma.
    Grau E; Tenias JM; Olaso MA; Ferrando I; Juan MT; Pastor E; Perez A; Real E
    Haematologica; 1999 Jul; 84(7):633-6. PubMed ID: 10406906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of a prothrombin complex concentrate (Octaplex) for rapid reversal of oral anticoagulation.
    Lubetsky A; Hoffman R; Zimlichman R; Eldor A; Zvi J; Kostenko V; Brenner B
    Thromb Res; 2004; 113(6):371-8. PubMed ID: 15226091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Interaction between tramadol and oral anticoagulants].
    Jensen K
    Ugeskr Laeger; 1997 Feb; 159(6):785-6. PubMed ID: 9045477
    [No Abstract]   [Full Text] [Related]  

  • 17. [Current biological surveillance of oral anticoagulant treatment].
    Helft G; Vacheron A; Samama MM
    Arch Mal Coeur Vaiss; 1995 Jan; 88(1):85-9. PubMed ID: 7646254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secondary prophylaxis of venous thromboembolism: rational use of oral anticoagulants.
    Piovella F; Siragusa S; Barone M; Beltrametti C; Carbone S; Vicentini L; Ascari E
    Haematologica; 1995; 80(2 Suppl):87-91. PubMed ID: 7543072
    [No Abstract]   [Full Text] [Related]  

  • 19. Changes in plasma warfarin levels and variations in steady-state prothrombin times.
    White RH; Zhou H; Romano P; Mungall D
    Clin Pharmacol Ther; 1995 Nov; 58(5):588-93. PubMed ID: 7586953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prevention of thromboembolic complications with adapted low-dose of antivitamins K after total hip prosthesis].
    Hernigou P; Février MJ; Kergrohen F
    Rev Chir Orthop Reparatrice Appar Mot; 1993; 79(7):577-85. PubMed ID: 8085039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.